The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30 milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant Oranienburg, Germany (TOB) relative to that of dexlansoprazole from a 30 mg or 60 mg capsule manufactured at Takeda Pharmaceutical Company Ltd. (Osaka, Japan) (TPC).
The drug being tested in this study is called dexlansoprazole. This study will compare bioavailability of dexlansoprazole from 30 mg and 60 mg dexlansoprazole delayed release capsules manufactured at TOB relative to the corresponding 30 mg and 60 mg dexlansoprazole delayed release capsules manufactured at TPC. The study will enroll approximately 104 participants. Participants will be randomly assigned (by chance, like flipping a coin) to 1 of the 4 treatment sequences: * Dexlansoprazole 30 mg TOB followed by Dexlansoprazole 30 mg TPC * Dexlansoprazole 30 mg TPC followed by Dexlansoprazole 30 mg TOB * Dexlansoprazole 60 mg TOB followed by Dexlansoprazole 60 mg TPC * Dexlansoprazole 60 mg TPC followed by Dexlansoprazole 60 mg TOB All participants will be asked to take single oral dose of dexlansoprazole at the same time on Day 1 of each Period. This single center trial will be conducted in the United States. The overall time to participate in this study is 18 days. Participants will visit the clinic on Day -1 and remained confined until Day 2 of Period 1 and 2. A washout period of minimum 5 days will be maintained between the doses in each Period. Participants will be contacted by telephone 10 (+/-2) days after the last dose of study drug for a follow-up assessment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
116
Dexlansoprazole delayed-release.
Dexlansoprazole delayed-release.
Dexlansoprazole delayed-release.
PRAHS Phase 1 unit
Salt Lake City, Utah, United States
Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole
Time frame: Day 1: pre-dose and at multiple time points (up to 24 hours) post-dose
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dexlansoprazole
Time frame: Day 1: pre-dose and at multiple time points (up to 24 hours) post-dose
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Dexlansoprazole
Time frame: Day 1: pre-dose and at multiple time points (up to 24 hours) post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dexlansoprazole delayed-release.